Births from embryos with highly elevated levels of mitochondrial DNA.


Journal

Reproductive biomedicine online
ISSN: 1472-6491
Titre abrégé: Reprod Biomed Online
Pays: Netherlands
ID NLM: 101122473

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 18 12 2018
revised: 19 03 2019
accepted: 21 03 2019
pubmed: 20 8 2019
medline: 25 9 2020
entrez: 18 8 2019
Statut: ppublish

Résumé

Conflicting data exist on the utility of quantification of mitochondrial DNA (mtDNA) levels as a predictor of blastocyst implantation in the IVF clinic. The current study determined whether blastocysts with highly elevated mtDNA levels could result in healthy pregnancies and births, and whether mitochondrial functional output might be a readout of cell stress in the embryo. mtDNA levels were determined in 109 blastocysts used in clinical transfers into 100 women, noting their clinical outcomes. In a separate set of embryos, mitochondrial function was quantified in a model of embryo stress, aneuploidy. Measurement of mtDNA levels made use of surplus material from the process of preimplantation genetic testing for aneuploidies, and followed recently proposed unifying guidelines for mtDNA quantification. Unusually high mtDNA levels did not preclude blastocyst implantation and healthy births. An analysis of 109 blastocysts showed no significant difference between mtDNA levels in implanted (n = 55) versus non-implanted (n = 54) blastocysts. No obvious differences in the degree of mitochondrial functional output were detected in a model of embryo stress. Measurement of mtDNA copy number might not provide any advantage in embryo prioritization and could lead to a deselection of blastocysts that would result in healthy pregnancies and births. Furthermore, the quantification of mitochondrial functional output in a model of cellular stress might suggest that mitochondria are not clear targets for biomarker identification as it relates to blastocyst viability. Any suggested link between mtDNA levels, mitochondria or their output with blastocyst transfer outcome requires further validation.

Identifiants

pubmed: 31420253
pii: S1472-6483(19)30373-6
doi: 10.1016/j.rbmo.2019.03.214
pii:
doi:

Substances chimiques

DNA, Mitochondrial 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

403-412

Informations de copyright

Copyright © 2019 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Auteurs

Andrea Victor (A)

Zouves Fertility Center, Foster City California, USA; School of Biosciences, University of Kent, Canterbury, UK.

Darren Griffin (D)

School of Biosciences, University of Kent, Canterbury, UK.

David K Gardner (D)

School of BioSciences, University of Melbourne, Parkville, Australia.

Alan Brake (A)

Zouves Fertility Center, Foster City California, USA.

Christo Zouves (C)

Zouves Fertility Center, Foster City California, USA; Zouves Foundation for Reproductive Medicine, Foster City California, USA.

Frank Barnes (F)

Zouves Fertility Center, Foster City California, USA; Zouves Foundation for Reproductive Medicine, Foster City California, USA.

Manuel Viotti (M)

Zouves Fertility Center, Foster City California, USA; Zouves Foundation for Reproductive Medicine, Foster City California, USA. Electronic address: manuel@zouvesfoundation.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH